Human metapneumovirus: An emerging threat among respiratory pathogens with rising cases in infants and young children

Human metapneumovirus (hMPV), first isolated in 2001, has garnered increasing recognition as a pivotal contributor to the global burden of respiratory illnesses, particularly in vulnerable populations such as infants and young children. This review seeks to illuminate the escalating threat posed by hMPV, underscoring its clinical and epidemiological prominence within the spectrum of respiratory pathogens. The investigation delves into the molecular and pathogenic intricacies of hMPV, exploring its transmission dynamics and the multifaceted factors driving its rising prevalence. Particular emphasis is placed on its clinical manifestations, which frequently emulate the severe presentations of respiratory syncytial virus (RSV), thereby complicating early diagnosis and effective management. A comprehensive methodology is employed, encompassing systematic reviews of clinical case reports, meta-analyses of contemporary epidemiological data spanning from 2014 to 2025, and computational modeling to elucidate the viral replication cycle, immune evasion mechanisms, and antigenic variability. Key findings highlight hMPV as a leading etiological agent of bronchiolitis and pneumonia, particularly in immunologically naïve, elderly, or immunocompromised populations. Alarmingly, the virus exhibits a pronounced capacity for seasonal epidemics and co-infections with other respiratory viruses, which synergistically amplify disease severity. These insights underscore an urgent need for advanced diagnostic methodologies, robust surveillance systems, and accelerated efforts in vaccine development. This research enriches the fields of virology and public health by deepening the understanding of hMPV's pathogenesis and epidemiology, identifying critical therapeutic targets, and proposing integrative strategies to enhance early detection. The practical implications lie in informing public health policies, improving clinical outcomes, and bolstering global preparedness for this emerging respiratory pathogen.